» Articles » PMID: 32286062

Both D- and L-Glucose Polyphosphates Mimic D--Inositol 1,4,5-Trisphosphate: New Synthetic Agonists and Partial Agonists at the Ins(1,4,5)P Receptor

Overview
Journal J Med Chem
Specialty Chemistry
Date 2020 Apr 15
PMID 32286062
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Chiral sugar derivatives are potential cyclitol surrogates of the Ca-mobilizing intracellular messenger d--inositol 1,4,5-trisphosphate [Ins(1,4,5)P]. Six novel polyphosphorylated analogues derived from both d- and l-glucose were synthesized. Binding to Ins(1,4,5)P receptors [Ins(1,4,5)PR] and the ability to release Ca from intracellular stores via type 1 Ins(1,4,5)PRs were investigated. β-d-Glucopyranosyl 1,3,4-tris-phosphate, with similar phosphate regiochemistry and stereochemistry to Ins(1,4,5)P, and α-d-glucopyranosyl 1,3,4-tris-phosphate are full agonists, being equipotent and 23-fold less potent than Ins(1,4,5)P, respectively, in Ca-release assays and similar to Ins(1,4,5)P and 15-fold weaker in binding assays. They can be viewed as truncated analogues of adenophostin A and refine understanding of structure-activity relationships for this Ins(1,4,5)PR agonist. l-Glucose-derived ligands, methyl α-l-glucopyranoside 2,3,6-trisphosphate and methyl α-l-glucopyranoside 2,4,6-trisphosphate, are also active, while their corresponding d-enantiomers, methyl α-d-glucopyranoside 2,3,6-trisphosphate and methyl α-d-glucopyranoside 2,4,6-trisphosphate, are inactive. Interestingly, both l-glucose-derived ligands are partial agonists: they are among the least efficacious agonists of Ins(1,4,5)PR yet identified, providing new leads for antagonist development.

Citing Articles

Substrate promiscuity of inositol 1,4,5-trisphosphate kinase driven by structurally-modified ligands and active site plasticity.

Marquez-Monino M, Ortega-Garcia R, Whitfield H, Riley A, Infantes L, Garrett S Nat Commun. 2024; 15(1):1502.

PMID: 38374076 PMC: 10876669. DOI: 10.1038/s41467-024-45917-5.


Inositol 1,4,5-trisphosphate receptors in cardiomyocyte physiology and disease.

Demydenko K, Ekhteraei-Tousi S, Roderick H Philos Trans R Soc Lond B Biol Sci. 2022; 377(1864):20210319.

PMID: 36189803 PMC: 9527928. DOI: 10.1098/rstb.2021.0319.


The discovery and development of IP3 receptor modulators: an update.

Gambardella J, Morelli M, Wang X, Castellanos V, Mone P, Santulli G Expert Opin Drug Discov. 2020; 16(6):709-718.

PMID: 33356639 PMC: 8169518. DOI: 10.1080/17460441.2021.1858792.


Inositol Adenophostin: Convergent Synthesis of a Potent Agonist of d--Inositol 1,4,5-Trisphosphate Receptors.

Su X, Dohle W, Mills S, Watt J, Rossi A, Taylor C ACS Omega. 2020; 5(44):28793-28811.

PMID: 33195933 PMC: 7659177. DOI: 10.1021/acsomega.0c04145.

References
1.
Tovey S, Sun Y, Taylor C . Rapid functional assays of intracellular Ca2+ channels. Nat Protoc. 2007; 1(1):259-63. DOI: 10.1038/nprot.2006.40. View

2.
Marchant J, Beecroft M, Riley A, Jenkins D, Marwood R, Taylor C . Disaccharide polyphosphates based upon adenophostin A activate hepatic D-myo-inositol 1,4,5-trisphosphate receptors. Biochemistry. 1997; 36(42):12780-90. DOI: 10.1021/bi971397v. View

3.
Jenkins D, Potter B . A Ca(2+)-mobilising carbohydrate-based polyphosphate: synthesis of 2-hydroxyethyl alpha-D-glucopyranoside 2',3,4-trisphosphate. Carbohydr Res. 1996; 287(2):169-82. DOI: 10.1016/0008-6215(96)00078-x. View

4.
Takahashi M, Kagasaki T, Hosoya T, Takahashi S . Adenophostins A and B: potent agonists of inositol-1,4,5-trisphosphate receptor produced by Penicillium brevicompactum. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1993; 46(11):1643-7. DOI: 10.7164/antibiotics.46.1643. View

5.
Mills S, Luyten T, Erneux C, Parys J, Potter B . Multivalent benzene polyphosphate derivatives are non-Ca-mobilizing Ins(1,4,5)P receptor antagonists. Messenger (Los Angel). 2014; 1(2):167-181. PMC: 3988618. DOI: 10.1166/msr.2012.1016. View